STUDY OF THE RELATIONSHIP BETWEEN THE DEVELOPMENT OF FIBROSIS PROCESSES AND THE FUNCTIONAL STATE OF THE HEART IN PATIENTS WITH CHRONIC HEART FAILURE

Authors

  • Abdigaffar G. Gadaev Researcher Tashkent Medical Academy, Uzbekistan
  • Guzel B. Shamsutdinova Researcher Fergana Public Health Medical Institute, Uzbekistan

Keywords:

Chronic heart failure, N-pro natriuretic peptide, aldosterone

Abstract

The development of fibrosis processes in patients with chronic heart failure is correlated with the functional state of the heart. This is also confirmed by positive changes in N-pro-natriuretic peptide and aldosterone indicators after treatments in patients involved in the study, as well as reliable positive improvement in cardiac functional status in those who received sacubitril + valsartan and dapagliflozin. It was demonstrated by highly reliable positive changes in end-systolic and diastolic cardiac volumes and left ventricular ejection fraction.

Downloads

Download data is not yet available.

References

Alzahrani, S., Alosaimi, M., Malibarey, W. M., Alhumaidi, A. A.,Alhawaj, A. H., Alsulami, N. J., Alsharari, A. S., Alyami,A. A., Alkhateeb, Z. A., Alqarni, S. M. et al. (2019). Saudi Family Physicians' Knowledge of Secondary Prevention of Heart Disease: A National Assessment Survey. Archieves of Pharmacy Practice, 10(4), 54-60.

Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285-1295.

Bhatt A.S., Ambrosy A.P., Dunning A., DeVore A.D., Butler J., Reed S., Voors A., Starling R., Armstrong P.W., Ezekowitz J.A., Metra M., Hernandez A.F., O'Connor C.M., Mentz R.J. The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF. Eur J Heart Fail. 2020 Jun;22(6):1022-1031.

Calvier L. Miana M., Reboul P. et al. Galectin-3 mediates aldosterone-induced vascular fibrosis // Atheroscler. Thromb. Vasc. Biol. — 2013. — Vol. 33 — P. 67–75.

Davis M.E., Richards A.M., Nicholls M.G., Yandle T.G., Frampton C.M., Troughton R.W. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 2006; 113(7): 977–985.

Eisenstein E.L., Nelson C.L., Simon T.A., Smitten A.L., Lapuerta P., Mark D.B. Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects with Heart Failure. Am Heart J 2002; 143(6): 1112–1117.

Esayan A.M., Nimgirova A.N. Mineralokortikoid receptor antagonists new extended roles in cardio-and nephroprotection // Медицинский совет № 5. 2018.

Groenewegen, A., Rutten, F. H., Mosterd, A., & Hoes, A. W. (2020). Epidemiology of heart failure. European Journal of Heart Failure, 22(8), 1342-1356;, Permadi, A. W., Hartono, S., Wahjuni, E. S., & Lestari, N. K. D. (2020). The Combination of Physical Exercise Programs in Patients with Heart Failure. International Journal of Pharmaceutical and Phytopharmacological Research, 10(1), 22-28.

Reibis R., Jannowitz C., Halle M., Pittrow D., Gitt A., Völler H. Management and outcomes of patients with reduced ejection fraction after acute myocardial infarction in cardiac rehabilitation centers. Curr Med Res Opin 2015; 31(2): 211–219.,

Richards A.M. Variability of NT-proBNP levels in heart failure: implications for clinical application. Heart 2007; 93(8): 899–900.

Shiba N, Shimokawa H. Chronic kidney disease and heart failure--Bidirectional close link and common therapeutic goal. J Cardiol. 2011 Jan;57(1):8-17.

Tang S., Peng D., Hu Y., Chen J. Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats. Eur Rev Med Pharmacol Sci 2015; 19(5): 759–766.

Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Cheng, S., Delling, F. N. et al. (2021). Heart Disease and Stroke Statistics-2021 Update: A Report from the American Heart Association. Circulation. 143(8):e254-e743.

Гуревич М.А., Кузьменко Н.А. Блокада альдостерона в лечении артериальной гипертензии (аспекты применения эплеренона). Кардиология. РМЖ «Медицинское обозрение» №11 от 31.05.2017 стр. 776-779.

Евдокимова А.Г., Коваленко Е.В., Евдокимов В.В., Ющук Е.Н., Стрюк Р.И. Антагонисты минералкортикоидных рецепторов: преимущества применения эплеренона (Иплерон) у больных хронической сердечной недостаточностью. журнал Поликлиника № Х(Х) 2019. С.1-6.

Downloads

Published

2024-01-30

How to Cite

Abdigaffar G. Gadaev, & Guzel B. Shamsutdinova. (2024). STUDY OF THE RELATIONSHIP BETWEEN THE DEVELOPMENT OF FIBROSIS PROCESSES AND THE FUNCTIONAL STATE OF THE HEART IN PATIENTS WITH CHRONIC HEART FAILURE. International Scientific and Current Research Conferences, 1(01), 107–114. Retrieved from https://orientalpublication.com/index.php/iscrc/article/view/1432

Issue

INNOVATION JUNCTION: COLLABORATIVE SOLUTIONS AT THE INTERSECT

Section

Articles

License

Copyright (c) 2024 Abdigaffar G. Gadaev, Guzel B. Shamsutdinova

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The content published on the International Scientific and Current Research Conferences platform, including conference papers, abstracts, and presentations, is made available under an open-access model. Users are free to access, share, and distribute this content, provided that proper attribution is given to the original authors and the source.